A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Graft Vs Host Disease (GVHD)
Dec 2008
Yes
MD
Study Director
Biovitrum AB
United States: Food and Drug Administration
20040213
NCT00189488
August 2005
December 2013
Name | Location |
---|